 TRACON Pharmaceuticals Inc NASDAQ:TCON has presented updated data from its Phase 1 study of TJ004309 uliledlimab and Tecentriq atezolizumab at the American Society of Clinical Oncology ASCO virtual annual meeting. In poster presentation 2511 -- entitled The safety, pharmacokinetics PK, pharmacodynamics PD and clinical efficacy of uliledlimab TJ004309, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer -- the company said data were presented from 20 refractory cancer patients with advanced or metastatic solid tumors treated with the combination of uliledlimab and atezolizumab. 